WeVote
Log In

Bill

Bill

HB 1223

ECONOMIC DEVELOPMENT: Establishes the Louisiana Clinical Trial Competitiveness and Patient Access Act

2026 Regular Session Introduced by Jack McFarland

Louisiana would create a statewide framework mandating participation by researchers and sponsors to accelerate early-phase clinical trials through standardized processes, timelines

Effective date: 06/09/2026.
0
WeVote Research Nonpartisan
Bill Summary · HB 1223

Summary of HB 1223 (2026) – Louisiana Early-Phase Clinical Trial Acceleration Framework

Purpose and Context

HB 1223 would establish a statewide framework to accelerate and coordinate early-phase clinical trials conducted in Louisiana. The underlying aim is to improve patient access to investigational therapies, strengthen the state’s biomedical research ecosystem, and attract private investment, all while operating within existing resources.

Key Provisions

  • New Chapter created: Adds Chapter 70 to Title 51 (Louisiana Revised Statutes) establishing the Louisiana Early-Phase Clinical Trial Acceleration Framework, with R.S. 51:3301–3310.

  • Definitions (standardized terms used throughout the framework):

    • Benchmark category, complete submission, contract research organization (CRO), covered clinical project (including early-phase, first-in-human, dose-escalation, precision medicine, rare disease, cell/gene therapy, biologic, or medical-device trials), department (Louisiana Economic Development), external Institutional Review Board (IRB), participation agreement, patient-access support, research entity, sponsor, among others.

  • Administration and coordination:

    • The Louisiana Department of Economic Development (LED) shall administer a clinical trial acceleration coordination function within existing resources.
    • LED may designate existing staff or units, enter into cooperative or similar agreements, and coordinate with public/private entities to support implementation, without creating new positions or requiring new funding unless legislatively provided.
    • The department may maintain a state registry of investigators/sites and verified capabilities (subject to confidentiality).

  • Participation and governance:

    • Participation in the framework is mandatory for all entities implementing a covered clinical project in Louisiana.
    • A research entity (providers, hospitals, academic institutions, CROs, etc.) must sign a participation agreement with LED or its designee.
    • The participation agreement sets expectations, including: benchmark categories, primary contacts, institution-specific addenda, local review categories for external IRB use, information sharing for performance evaluation, escalation procedures, and any capacity or participation conditions.

  • Process acceleration and coordination:

    • LED must publish standardized completeness checklists and intake procedures, plus model contract provisions and budget guidance for benchmark categories.
    • LED can coordinate feasibility, site identification, and issue resolution with sponsors, CROs, and site-selection teams; may maintain a sponsor-facing coordination function and provide a consolidated statewide feasibility response.
    • A registry of investigators/sites and verified capabilities may be used to support coordination and outreach.

  • Activation and timing standards (for each covered clinical project):

    • Acknowledgment of receipt within 2 business days (not a commitment).
    • Completeness confirmation or a single consolidated deficiency notice within 5 business days (complete by day 6 if no notice).
    • No serial deficiencies for items reasonably identifiable initially, except sponsor-requested or newly arising issues.
    • Sponsor feasibility response/engagement determination within 10 business days after required materials.
    • Concurrent, non-duplicative startup reviews (contracts, budgets, coverage, etc.) where possible.
    • Initial contract and budget responses within 10 business days.
    • Escalation procedures if benchmarks are missed, potentially up to executive-level review.

  • IRB considerations:

    • Where allowed by federal law, reliance on external IRBs is permitted, with written justifications required for nonreliance (local review, participant safety concerns, etc.).

  • Reporting and confidentiality:

    • Annual, aggregated, non-identifiable reporting on performance benchmarks, timelines, barriers, and recommendations.
    • Public reports will exclude patient-identifying information and sponsor proprietary terms.

  • Limitations and compliance:

    • Framework does not create warranties of performance or private causes of action solely based on benchmark outcomes.
    • Participation may be modified or conditioned for repeated failure to meet benchmarks.
    • Public reporting designed to protect sensitive information and honor confidentiality.

  • Funding and effective date:

    • Implementation within existing resources unless otherwise provided by law.
    • Effective upon gubernatorial action (signature or expiration without signature).

Potential Impact

  • Creates a centralized, standardized process intended to streamline early-phase trials in Louisiana.
  • Promotes transparency through public, aggregated performance data while safeguarding patient privacy and proprietary information.
  • Encourages collaboration among sponsors, CROs, research entities, IRBs, and site-selection teams.
  • May improve speed-to-activation metrics, such as feasibility responses, contract/budget timelines, and site activation.
  • The mandatory participation requirement ensures statewide alignment but relies on existing resources for implementation.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.